Vyriad Begins Phase 1 Clinical Trial for Lead In Vivo CAR T Cell Therapy VV169 Following FDA Acceptance of IND Application

Vyriad has opened enrollment for a Phase 1 clinical trial of VV169, its in vivo CAR T-cell therapy for multiple myeloma, at Mayo Clinic. The early-stage trial marks a development milestone for the company’s oncology pipeline, but clinical efficacy and safety data remain pending.